CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

After the shigella technology transfer, GSK will work with Bharat to design the phase 3 trial and support its partner’s search for external funding.

The transfer portal for college baseball has been open for nearly a week, and the TCU Horned Frogs have had their share of players depart. From household names to freshmen who never got their shot ...

Trump’s effort to bolster American manufacturing is unproductive.

A number of Nintendo Switch 2 owners are learning the hard way that they shouldn't have declined the system transfer prompt.

GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.

British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing, we ...

By Kelly Cloonan Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint.

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.